Breaking News

TAAV’s Synthetic DNA Material Approved for Use in Clinical Trial

dbDNA material to be used in upcoming approved Huntington's disease study in France.

Author Image

By: Charlie Sternberg

Associate Editor

TAAV Biomanufacturing Solutions, has announced the anticipated first use in a clinical trial of its doggybone DNA (dbDNA), a precisely engineered synthetic DNA material.   TAAV-produced dbDNA is a component of an Asklepios BioPharmaceutical Inc. (AskBio) gene therapy candidate for the treatment of early-stage Huntington’s disease, which was recently authorized by France’s National Agency for Safety of Medicines and Health Products (ANSM) for an upcoming Phase I/II clinical trial. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters